骨保护素系统与冠状动脉粥样硬化性心脏病的研究进展

Osteoprotegerin system and coronary atherosclerotic heart disease:an update

骨保护素(OPG)是肿瘤坏死因子(TNF)超家族的一种可溶性分泌型糖蛋白,与核因子κB受体活化因子配体(RANKL)、核因子κB受体活化因子(RANK)以及肿瘤坏死因子相关凋亡诱导配体(TRAIL)共同组成骨保护素系统。大量临床及实验研究证实骨保护素系统参与内皮功能调节、炎症反应、氧化应激及细胞凋亡等生理过程,其有望成为冠心病发生、发展、严重程度及其远期预后的生物学标志物,为冠心病的早期诊断及治疗提供新的可行途径。本文就骨保护素系统在冠心病发生、发展中的生物学效应、作用机制及未来的临床应用前景进行综述。

Osteoprotegerin(OPG), as a member of the tumor necrosis factor(TNF) superfamily, is a soluble secretaryglycoprotein, which is accompanied with NF-κB receptor activator(RANK), NF-κB receptor activator ligand(RANKL) andtumor necrosis factor-related apoptosis-inducing ligand(TRAIL) to form osteoprotegerin system. A large number of clinicaland experimental studies have confirmed that osteoprotegerin system participates in physiological processes such asendothelial function, inflammatory reaction, oxidative stress and apoptosis, which is expected to be a biomarker for theoccurrence, development, severity and long-term prognosis of coronary heart disease. In this paper, we summarized thebiological effects and mechanism of the osteoprotegerin system in the occurrence and development of coronary heart diseaseand its future clinical application.